Divalproex Sodium Tablet, Extended Release
FDA Label NDC 55154-2345

63 label sections · Submitted to the FDA by Cardinal Health 107, Llc · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Cardinal Health 107, Llc for the product Divalproex Sodium (NDC 55154-2345). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding warning: life threatening adverse reactions, 1.1 mania, 1.2 epilepsy, 1.3 migraine, 1.4 important limitations, 2 dosage and administration, 2.1 mania, 2.2 epilepsy, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Label Section Quick Index

Package/Label Display Panel

NDC 55154-2345-0

DIVALPROEX SODIUM

EXTENDED-RELEASE TABLETS, USP

500 mg*

(Valproic Acid Activity)

10 TABLETS

500mg Bag Label (Eb856e10 53b1 45b8 A784 Efae752c7cfe 00)

500mg Bag Label (Eb856e10 53b1 45b8 A784 Efae752c7cfe 00)

* Please review the disclaimer below.